Literature DB >> 29761229

Idiopathic Pulmonary Fibrosis Among Young Patients: Challenges in Diagnosis and Management.

Gabriela Leuschner1, Fredrik Reiter2, Florian Stocker2, Alexander Crispin3, Nikolaus Kneidinger2, Tobias Veit2, Friederike Klenner2, Felix Ceelen2, Gregor Zimmermann2, Hanno Leuchte4, Simone Reu5, Julien Dinkel6, Jürgen Behr2, Claus Neurohr2.   

Abstract

INTRODUCTION: Idiopathic pulmonary fibrosis (IPF) is considered a disease of older patients, being rare in patients ≤ 50 years. Still, IPF can occur in younger patients, but this particular patient group is not well characterised so far. The aim of this study was to compare the diagnostic certainty, clinical features, comorbidities and survival in young versus older IPF patients.
METHODS: We reviewed our medical records from February 2011 until February 2015, to identify IPF patients, who were then classified as young (≤ 50 years) or older IPF (> 50 years). Radiographic and histological findings, lung function parameters, comorbidities, disease progression and survival were analysed and compared between the two groups.
RESULTS: Of 440 patients with interstitial lung disease, 129 patients with IPF were identified, including 30 (23.3%) ≤50 years and 99 (76.7%) > 50 years. There were no differences between age groups in baseline demographics; younger patients were less likely to have a confirmed diagnosis by high-resolution computed tomography (p = 0.014), more likely to require a biopsy (p = 0.08) and less likely to have received antifibrotic therapy (p = 0.006). Despite an overall limited prognosis, younger patients had a significantly better median survival after diagnosis (p = 0.0375), with a significantly higher proportion of older patients dying due to respiratory failure (p = 0.0383).
CONCLUSION: IPF patients under the age of 50 years have similar features and clinical course compared to older IPF patients. These patients should be diagnosed by adopting a multidisciplinary team approach, potentially benefitting from earlier intervention with effective antifibrotic therapy.

Entities:  

Keywords:  Clinical course; Comorbidity; Idiopathic pulmonary fibrosis; Survival; Young patients

Mesh:

Substances:

Year:  2018        PMID: 29761229     DOI: 10.1007/s00408-018-0123-9

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  22 in total

1.  ATS statement: guidelines for the six-minute walk test.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-07-01       Impact factor: 21.405

2.  Characterisation of patients with interstitial pneumonia with autoimmune features.

Authors:  Justin M Oldham; Ayodeji Adegunsoye; Eleanor Valenzi; Cathryn Lee; Leah Witt; Lena Chen; Aliya N Husain; Steven Montner; Jonathan H Chung; Vincent Cottin; Aryeh Fischer; Imre Noth; Rekha Vij; Mary E Strek
Journal:  Eur Respir J       Date:  2016-04-21       Impact factor: 16.671

Review 3.  Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium.

Authors:  Steven D Nathan; Oksana A Shlobin; Nargues Weir; Shahzad Ahmad; Julienne M Kaldjob; Edwinia Battle; Michael J Sheridan; Roland M du Bois
Journal:  Chest       Date:  2011-07       Impact factor: 9.410

4.  Incidence and prevalence of idiopathic pulmonary fibrosis.

Authors:  Ganesh Raghu; Derek Weycker; John Edelsberg; Williamson Z Bradford; Gerry Oster
Journal:  Am J Respir Crit Care Med       Date:  2006-06-29       Impact factor: 21.405

Review 5.  Definitions and diagnosis of pulmonary hypertension.

Authors:  Marius M Hoeper; Harm Jan Bogaard; Robin Condliffe; Robert Frantz; Dinesh Khanna; Marcin Kurzyna; David Langleben; Alessandra Manes; Toru Satoh; Fernando Torres; Martin R Wilkins; David B Badesch
Journal:  J Am Coll Cardiol       Date:  2013-12-24       Impact factor: 24.094

6.  Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK.

Authors:  J Gribbin; R B Hubbard; I Le Jeune; C J P Smith; J West; L J Tata
Journal:  Thorax       Date:  2006-07-14       Impact factor: 9.139

7.  Frequency and implication of autoimmune serologies in idiopathic pulmonary fibrosis.

Authors:  Teng Moua; Fabien Maldonado; Paul A Decker; Craig E Daniels; Jay H Ryu
Journal:  Mayo Clin Proc       Date:  2014-03       Impact factor: 7.616

8.  [German guideline for diagnosis and management of idiopathic pulmonary fibrosis].

Authors:  J Behr; A Günther; W Ammenwerth; I Bittmann; R Bonnet; R Buhl; O Eickelberg; R Ewert; S Gläser; J Gottlieb; C Grohé; M Kreuter; C Kroegel; P Markart; C Neurohr; M Pfeifer; A Prasse; N Schönfeld; J Schreiber; H Sitter; D Theegarten; A Theile; A Wilke; H Wirtz; C Witt; H Worth; P Zabel; J Müller-Quernheim; U Costabel
Journal:  Pneumologie       Date:  2013-01-16

9.  A multidimensional index and staging system for idiopathic pulmonary fibrosis.

Authors:  Brett Ley; Christopher J Ryerson; Eric Vittinghoff; Jay H Ryu; Sara Tomassetti; Joyce S Lee; Venerino Poletti; Matteo Buccioli; Brett M Elicker; Kirk D Jones; Talmadge E King; Harold R Collard
Journal:  Ann Intern Med       Date:  2012-05-15       Impact factor: 25.391

10.  Haemodynamic changes in pulmonary hypertension in patients with interstitial lung disease treated with PDE-5 inhibitors.

Authors:  Gregor S Zimmermann; Werner von Wulffen; Patrick Huppmann; Tobias Meis; Franziska Ihle; Jens Geiseler; Hanno H Leuchte; Amanda Tufman; Juergen Behr; Claus Neurohr
Journal:  Respirology       Date:  2014-04-03       Impact factor: 6.424

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.